Farnesyltransferase inhibitors have been tested in clinical trials for the treatment of tumours. In sepsis, the binding of programmed death 1 (PD-1) to programmed death ligand 1 (PD-L1) promotes lymphocyte apoptosis and decreases cytokine expression, thus affecting survival rates. The PD-1/PD-L1 pathway plays an important role in chronic viral infection, bacterial infection and sepsis. However, the precise immunosuppressive and antiinflammatory functions of this pathway remain poorly understood. In our previous study, the induction of sepsis by caecal ligation and puncture (CLP) resulted in increased farnesyltransferase activity and farnesylated protein levels in the spleen relative to sham treatment. However, the effect of inhibition of farnesyltransferase activity on overall survival rates in patients with sepsis and the specific signalling pathway involved remain to be investigated. In this study, mice with CLP-induced sepsis were treated with farnesyltransferase inhibitor (FTI-277), and PD-L1 expression on septic spleen lymphocytes was examined. Flow cytometric analysis revealed that PD-L1 is expressed constitutively on lymphocytes and that PD-L1 protein expression was up-regulated strongly following CLP. FTI-277 downregulated PD-L1 mRNA and protein expression on septic spleen lymphocytes in a dose-dependent manner. This effect was associated closely with nuclear factor kappa B (NF-jB). In addition, the significant damping effect of FTI-277 on the PD-L1 signal promoted interferon (IFN)-g secretion, interleukin (IL)-2 production and splenocyte proliferation in response to anti-CD3
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Programmed death 1 (PD-1) is a co-inhibitory receptor that plays an important role in the modulation of immune responses [5] . PD-1 has two main ligands: PD-L1 and PD-L2; of these, PD-L1 is expressed broadly on haematopoietic and non-haematopoietic cells, including T cells, B cells and dendritic cells (DCs) [6] . Both PD-1 and its ligand programmed death ligand-1 (PD-L1) are crucial modulators of host immune responses during sepsis [7] : studies in PD-L1 knock-out mice support the finding that PD-L1 acts as the primary regulatory counter receptor for the inhibitory function of PD-1 [8] . Furthermore, antagonism of PD-L1 has been shown to block the interaction between PD-1 and PD-L1 [9, 10] . These findings imply that the maintenance of various immune responses relies upon the structure of the cell surface. Accordingly, we hypothesized that blockade of the interaction between PD-1 and PD-L1 should result in inhibition of the host immune response, thereby representing a potential strategy for the treatment of sepsis.
Numerous studies in animals have shown that hydroxymethylglutaryl-CoA synthase (HMG-CoA) reductase inhibitors (statins) decrease mortality in septic or infected mice [11, 12] . The beneficial effects of statins in sepsis are independent of their cholesterol-lowering effects. Statins decrease the production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate by inhibiting the ratelimiting enzyme of the mevalonate (MVA) pathway, thereby reducing protein isoprenylation, i.e. farnesylation and geranylgeranylation. Farnesyltransferase inhibitors have similar effects on the MVA pathway to those of statins. Both statins and farnesyltransferase inhibitors have been shown to reduce mortality following lipopolysaccharide (LPS) challenge in mice [13] .
Our preliminary data demonstrated that statin reduced LPS-induced mortality significantly and increased survival in mouse xenografts [13] . We first reported that the induction of sepsis by caecal ligation and puncture (CLP) resulted in increases in farnesyltransferase activity, the number of farnesylated proteins in the spleen, levels of bacteria and macrophages in peripheral blood and the concentration of regulatory T cells (T regs ) relative to those following a sham operation [14] . Additionally, we have shown previously that farnesyltransferase inhibitors reduce the number of CD4 1 T cells effectively as well as inducing PD-L1 and PD-1 over-expression [14] . This basic research indicates that the PD-L1 signalling pathway may be an ideal target for regulating the immune response in sepsis. However, the mechanism of action of farnesyltransferase inhibitors and the role of the PD-L1 signalling pathway in septic mice remain unknown. Here, we show that farnesyltransferase inhibitors modulate immune responses in septic mice by down-regulating PD-L1 expression on spleen lymphocytes, and that this effect is largely nuclear factor kappa B (NF-jB)-dependent.
Materials and methods

Animals
Male C57BL/6 mice at 7 weeks of age, purchased from the Experimental Animal Research Center of HuBei province, were used for this study. The study protocol was approved by the Institutional Animal Care Committee of Wuhan Union Hospital. The animal care facility at which experiments were performed is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The mice were housed in a pathogen-free animal facility maintained at 258C and illuminated by 12-h light/dark cycles. FTI-277 [25 mg/kg body weight intraperitoneally (i.p.); Sigma-Aldrich, St Louis, MO, USA] was administered to mice at 2 h after CLP or sham procedure. Mice in the control group were treated with monoclonal antibodies (mAbs) (molecule antibodies) against NF-jB inhibitors/ anti-oxidants MIH1 (50 mg/200 ml body weight, i.p.; eBioscience, San Diego, CA, USA) and pyrrolidine dithiocarbamate (PDTC) (100 mg/kg body weight, i.p.; Beyotime Institute of Biotechnology, Jiangsu, China) 2 h after CLP was performed. FTI-277 was dissolved in sterile distilled water and diluted with phosphate-buffered saline (PBS) just before injection.
Caecal ligation and puncture
CLP was performed to induce sepsis in the mouse model. In brief, mice were anaesthetized with pentobarbital sodium at a dose of 50 mg/kg (body weight, i.p.). After externalization, the ventral trunk was prepared with 70% ethanol. A midline incision ($1 cm) was made to expose the cecum in the abdomen. The caecum was then punctured twice all the way through with a sterile 18-gauge needle and compressed to extrude faecal contents. Caecum was relocated, and 5/0 sutures were used to close the peritoneum and skin. Sham surgery was performed in control mice. During sham (control) surgeries, the caecum was exposed in the same manner as during CLP surgeries, but was neither ligated nor punctured. Twenty-four hours after induction of endotoxaemia or CLP, mice were resuscitated by injecting subcutaneously (s.c.) prewarmed normal saline (0Á1 ml/g body weight). Mice were euthanized humanely at 24 h after CLP or sham procedure, and their tissues collected for immunohistochemistry, biochemical analyses, reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry. The mice were euthanized with an overdose of pentobarbital sodium (200 mg/kg body weight, i.p.).
Histology and immunohistochemistry
Spleens were harvested at 24 h after CLP. The samples were fixed immediately in 4% paraformaldehyde phosphatebuffered solution after rinsing in PBS. The fixed specimens were then dehydrated, cleared and embedded in paraffin. The blocks were cut into 3-lm thick sections using a rotary microtome and placed onto polypropylene microscope slides (ThermoFisher Scientific, Waltham, MA, USA). In order to assess apoptosis, paraffin-embedded spleen sections were stained for terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) PD-L1 and spleen lymphocyte activation using the DeadEnd Fluorometric TUNEL System (Promega, Madison, WI, USA). The numbers of TUNEL-positive nuclei were normalized to those of all nuclei visualized with 4,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). The sections were stained additionally with an immunoperoxidase TUNEL system (Apotag plus peroxidase in situ apoptosis kit; Millipore, Temecula, CA, USA) and counterstained with methyl green (SigmaAldrich), which dyes the chromatin to confirm further the results obtained by fluorometric TUNEL staining. The sections were counterstained using MayerL staining.
Spleen lymphocyte preparation
After CLP, spleens were removed aseptically at 16 h. Harvested spleens were placed immediately in 15 ml of ice-cold PBS. Then, splenocytes were passed through a 70-lm cell strainer to acquire a single cell suspension. Red blood cells were lysed with a red blood cell lysis reagent (eBioscience). Cells were washed twice with PBS and resuspended in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) penicillin-streptomycin and 10 mM HEPES, pH 7Á5. After incubation at 378C in a humidified atmosphere of 5% CO 2 , 95% air for 2 h, floating cells were collected and CD4 1 T cells were isolated for proliferation and cytokine secretion assays using flow cytometry.
Flow cytometric analysis
Flow cytometric analysis of apoptosis. Cells were trypsinized, resuspended in PBS and centrifuged at 150 g for 5 min. After washing twice with PBS, cells were examined for apoptosis using the annexin V-fluorescein isothiocyanate/propidium iodide (FITC/PI) cell death detection kit. Briefly, 5 ml of FITC-conjugated annexin V and 5 ml of PI were added to the suspension, and cells were incubated for 15 min in the dark at room temperature. The samples were analysed using a flow cytometer (FACSCalibur; BD Biosciences, Heidelberg, Germany) within 30 min after staining.
Flow cytometric analysis of surface antigen PD-L1. Surface expression of immune molecules was quantified by flow cytometry on a fluorescence-activated cell sorter. Isolated spleen lymphocytes were treated with 1Á5 ll of anti-PD-L1 (0Á2 mg/ml) antibodies (BD Pharmingen, San Diego, CA, USA), incubated for 30 min at 48C and centrifuged at 2236g for 2 min. Then, supernatants were decanted and washed twice with PBS [5% bovine serum albumin (BSA)] and then resuspended in PBS (5% BSA) for flow cytometric analysis of surface antigen PD-L1.
RT-PCR
RT-PCR was used to analyse PD-L1 mRNA expression on spleen lymphocytes. Mice were injected with FTI-277 (body weight, i.p.) at various doses (25 mg/kg) for 24 h. Spleen samples were washed, and total RNA was isolated using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). All RNA samples were quantitated by measurement of optical density (OD) at 260 nm. Semiquantitative RT-PCR was performed using a two-step PCR (Takara, Otsu, Japan) kit, in accordance with the manufacturer's instructions. Realtime RT-PCR analyses were performed as described previously [15] , using 10 ng of cDNA and TaqMan probes (Applied Biosystems) for PD-L1 on a Mastercycler EP Realplex (Eppendorf North America, New York, NY, USA). Specific primer sequences for PD-L1 were conducted. PCR products were separated by electrophoresis on a 1% agarose gel and visualized by ethidium bromide staining. The results were analysed using a PhosphorImager (PDQUEST; Bio-Rad, Hercules, CA, USA).
Western blotting
The expression of PD-L1, NF-jB p65, p-NF-jB p65 and pIjB was analysed by Western blotting. Spleen lymphocytes were pretreated with or without FTI-277 for 2 h. The ncnucleus/plasma protein was extracted using an nc-nucleus/ plasma protein extraction kit (CwbioTech, Nanjing, China). The total protein was extracted using a total protein extraction kit (KeyGEN BioTECH, Beijing, China), and protein concentrations were determined using the Bradford protein assay (Bio-Rad) with BSA as the standard. All samples were solubilized in Laemmli's sample buffer by boiling, separated on 8-12% sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE) gels, transferred to polyvinylidene difluoride (PVDF) membranes, blocked with 5% milk or 5% BSA, and resuspended in PBS-Tween (PBST) for 2 h at room temperature. The proteins were then blotted with primary antibodies including those against PD-L1, NF-jB p65, p-NF-jB p65 and p-IjB (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at room temperature. b-actin and lamin B were used as loading controls. The Western blotting results were analysed by calculating the grey value of the band using Quantity One software, which indicated expression levels.
Cell Counting Kit-8 (CCK-8) assay
The proliferation of spleen lymphocytes was also measured using CCK-8 reagents (Beyotime). Anti-CD3 (2 lm g/ml), anti-CD28 (2 lm g/ml) and 3 ml of PBS were added to each well of a six-well plate, which was sealed and incubated at 48C overnight. Then, the six-well plate was washed twice with PBS. Cells were then resuspended in RPMI-1640 medium at a density of 6 3 10 5 /ml and cultured in an incubator. After 2 days, cytokine IL-2 (60 U/ml) was added to the medium, mixed thoroughly, and cells were cultured. Cells were seeded in 96-well plates. Ten microlitres of CCK8 solution was added to 100 ll of culture medium and incubated at 378C for 4 h. The OD was determined using a microplate reader (MULTISKAN MK3; ThermoFisher) with a reference wavelength of 450 nm.
Statistical analysis
All enzyme-linked immunosorbent assay (ELISA), PCR and flow cytometric data presented are representative of at least three independent experiments. Statistical analysis was performed on complete data sets from two of the three independent experiments. A P-value of < 0Á05 indicated statistical significance for all analyses. All values are expressed as mean and standard error of the mean (mean 6 s.e.m.).
Results
Expression of PD-L1 in spleen lymphocytes of shamoperated and septic mice
The localization of PD-L1 expression on spleen lymphocytes was analysed by flow cytometry. As shown in Fig. 1a , PD-L1 was expressed constitutively on spleen lymphocytes, both in the sham group and the sepsis group. Furthermore, strong expression of PD-L1 was observed in the lymphocytes of mice after CLP.
In order to examine the expression of PD-L1 in the spleen quantitatively, we performed real-time PCR. Our results indicated a threefold significant increase in the expression of PD-L1 mRNA on spleens of septic mice 24 h after CLP challenge relative to the sham group (Fig. 1c) (P < 0Á01). As shown in Fig. 1b , Western blot analysis also demonstrated that CLP increased PD-L1 protein expression markedly on splenic lymphocytes.
Taken together, the present mRNA transcription and protein expression data reveal an essential role of PD-L1 in the spleens of mice challenged by CLP-induced sepsis.
FTI-277 down-regulates PD-L1 expression and inhibits PD-L1 transcription in sepsis-induced spleen lymphocytes
In order to explore the immunoregulatory mechanisms of FTI-277, the effect of this farnesyltransferase inhibitor on PD-L1 expression was examined. Septic mice were As shown in Fig. 2a , FTI-277 induced down-regulation of PD-L1 in septic spleen lymphocytes in a dose-dependent manner. After treatment with FTI-277, PD-L1 expression was reduced significantly, reaching the lowest value at 25 mg/kg FTI-277. Therefore, we used a FTI-277 concentration of 25 mg/kg in the present study. As also shown in Fig. 2b , FTI-277 treatment decreased PD-L1 protein expression substantially on spleen lymphocytes of septic mice compared with that observed following CLP alone. In addition, Fig. 2a shows that FTI-277 did not change PD-L1 expression on the spleen lymphocytes of sham-operated mice. Similar results were indicated by Western blot analysis (Fig. 2b) .
In order to confirm that the inhibitory effect of FTI-277 on PD-L1 protein synthesis was parallel to that on mRNA transcription, mice subjected to CLP were treated with FTI-277 (25 mg/kg) and PD-L1 mRNA expression was analysed by RT-PCR. As shown in Fig. 2c , the PD-L1 mRNA expression of the CLP group was increased significantly. In contrast, the level of PD-L1 mRNA was reduced dramatically in spleen lymphocytes of FTI-277-treated septic mice relative to that in mice subjected to CLP alone. Additionally, compared with that in the sham-treated group, PD-L1 mRNA expression in spleen lymphocytes appeared to be elevated modestly in FTI-277-treated sham mice; however, the difference was not statistically significant (P > 0Á10).
FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation
In order to determine further whether the functional relevance of FTI-277 inhibits PD-L1 expression on spleen lymphocytes, we examined its effects on spleen lymphocyte activation.
Using freshly purified septic spleen lymphocytes, we attempted to verify the hypothesis that spleen lymphocyte activation is promoted by FTI-277-induced damping of PD-L1 expression and that this is mediated via the modulation of the ratio of apoptotic cells, the secretion of cytokines and lymphocyte proliferation.
In order to examine the correlation between FTI-277 and lymphocyte activation, we first performed flow cytometric analysis to measure the percentage of apoptotic lymphocytes. Our results (Fig. 3a) indicate a significant increase in the percentage of apoptotic cells after CLP. But in sham group, the use of FTI-277 has no impact on apoptosis. Interestingly, when mice were treated with FTI-277 or PD-L1 mAbs (MIH1) after CLP, we observed that the percentage of apoptotic cells decreased significantly. Secondly, there were few TUNEL-positive cells in normal mice (Fig. 3b) . In contrast, the ratio of TUNEL-positive cells increased in mice subjected to CLP. However, FTI-277 (25 mg/kg) treatment resulted in a decrease in the number of TUNEL-positive cells in mice that had undergone CLP. Additionally, as shown in Fig. 3a ,b, the effects of FTI-277 treatment were in line with those observed following treatment with PD-L1 mAbs (MIH1).
Mice were subjected to CLP or sham surgery and 2 h later were injected with FTI-277. Sixteen hours after these procedures, dissociated splenocytes were cultured with anti-CD3 1 C D28 antibody. After 24 h, spleen cells were centrifuged, and the supernatant was collected to measure the concentration of IFN-g and IL-2. As shown in Fig. 3c,d , FTI-277 treatment promoted IFN-g and IL-2 secretion in spleen cells relative to those without treatment; in the former, the level of IFN-g and IL-2 secretion was close to that in sham-treated mice. In the sham group, the secretion of IFN-g and IL-2 following FTI-277 treatment was found to decline; however, the observed difference was not statistically significant. We confirmed that this effect was dependent upon the PD-L1 signal, as the specific PD-L1-blocking mAbs (MIH1) increased IFN-g and IL-2 production greatly. In addition, we have shown previously that sepsis-associated suppression of IFN-g secretion is ameliorated by FTI-277 [14] . Cell viability was measured using the CCK-8 assay. The rate of proliferation and clonogenic potential were compared among the five groups. As shown in Fig. 3e , CLP elicited a substantial decrease in the proliferation of spleen lymphocytes. However, the proliferation rate of spleen lymphocytes was enhanced significantly in septic mice following treatment with FTI-277 or PD-L1-specific blocking mAbs (MIH1), suggesting that the latter increase cell proliferation ability.
FTI-277 down-regulates PD-L1 expression on septic spleen lymphocytes in an NF-jB-dependent manner
The transcriptional factor NF-jB is activated rapidly in patients with sepsis [16] . In turn, activated NF-jB influences the expression of a large number of genes, including PD-L1 [17] . A study that used siRNA to knock down p65 expression in order to show its role in the regulation of PD-L1 expression found that levels of PD-L1 mRNA were reduced in p65 knock-down non-small-cell lung cancer (NSCLC) cells, suggesting that p65 regulates PD-L1 expression [18] . FTI-277 is thought to be associated closely with suppression of the NF-jB signalling pathway, owing mainly to its immunomodulatory properties and antiinflammatory activity. Therefore, we attempted to elucidate whether the FTI-277-induced inhibition of PD-L1 expression on spleen lymphocytes is mediated through the suppression of NF-jB transcription. FTI-277 or PDTC (NF-jB inhibitor/anti-oxidant) were injected into mice, and the activation and nuclear translocation of NF-jB was examined by Western blotting. NF-jB exists in unstimulated cells as a transcriptional dimer (p50 and p65 subunits) that is sequestered in the cytoplasm by the inhibitor protein IjB. Upon cell activation, IjB is phosphorylated and degraded, releasing NF-jB subunit, which allows NF-jB to translocate to the nucleus and promote the transcription of target genes. The results revealed slight bands for cytoplasmic and nuclear p65 in the sham group; in contrast, the group treated by CLP exhibited a decrease in cytoplasmic p65 and an increase in nuclear p65, suggesting that CLP treatment activates NF-jB in spleen lymphocytes (Fig. 4a,b) . Surprisingly, FTI-277 inhibited significantly the sepsis-induced phosphorylation of NF-jB p65 and IjB. We investigated the cytoplasmic translocation of NF-jB p65 under the same conditions and found that NF-jB p65 accumulated in the cytoplasm (Fig. 4a) , whereas the levels of nuclear NF-jB p65 decreased (Fig. 4b ) upon exposure to FTI-277. Moreover, after treatment with FTI-277, P-IkB and P-p65 levels in total protein were reduced (Fig. 4c,d) . Similar effects were observed in the PDTC (NF-jB inhibitor/anti-oxidant) group. Given the inhibitory effect of FTI-277 in NF-jB-mediated cell activation, these results suggest PD-L1 and spleen lymphocyte activation that FTI-277 inhibits PD-L1 expression in a manner largely dependent upon the nuclear translocation of NF-jB p65.
Discussion
FTI-277 has been found to exhibit potent anti-inflammatory and immunosuppressive properties, indicating the potential of farnesyltransferase inhibition as a therapeutic approach for the treatment of inflammation [19] . Numerous studies have attempted to elucidate the molecular mechanisms underlying the immunosuppressive effects of these compounds. Our work shows that FTI-277 inhibits the expression of costimulatory molecule PD-L1 on CD4
1 T cells and plays a key role in promoting spleen lymphocyte activation, thereby providing novel insights into the mechanism of action and clinical utility of farnesyltransferase inhibitors in sepsis. We have reported previously that protein farnesylation and farnesyltransferase activity are elevated in septic mice. In the present work, the increase in farnesylated protein levels in septic mice was reversed by treatment with FTI-277. In addition, FTI-277 attenuated farnesyltransferase activity in septic mice. Furthermore, FTI-277 was found to reverse or mitigate sepsis-induced apoptosis in spleens, increase the number of splenic CD4 forkead box protein 3 (FoxP3) T regs and suppress IFN-g secretion and proliferation of splenocytes in response to anti-CD3 1 CD28 antibodies in mice. Moreover, the inhibition of farnesyltransferase prevented functional derangements in splenic T cells during the early stages of severe sepsis [14] .
The major features of sepsis-induced immune suppression include T cell dysfunction, which is characterized by apoptosis of splenic T cells, increased CD4 FoxP3 T regs , suppression of type 1 helper (Th1) T cell response (e.g. IFN-g and IL-2 secretion) and a shift from a Th1 to an anergic or Th2 immune phenotype in mice [20] [21] [22] [23] . Numerous studies have shown that the production of IFNg and IL-2 is decreased in septic spleen lymphocytes [14, 24, 25] . However, sepsis-associated suppression of IFNg and IL-2 secretion by splenocytes was ameliorated by FTI-277 treatment. IFN-g and IL-2 have antiinflammatory properties; however, as a proinflammatory cytokine, IFN-g, which exerts its anti-inflammatory properties mainly by suppressing T-helper 17 cells and IL-2, can constrain IL-17 production [26] .
The expression of co-stimulatory molecules enables antigen-presenting cells to initiate and maintain effective T cell responses. Impaired PD-1 : PD-L1 function plays an important role in a variety of autoimmune diseases, and PD-L1 inhibits T cell responses through engagement with PD-1 [27] . Moreover, studies by Rabe et al. [28] indicate Total protein, cytoplasmic protein and nuclear protein were isolated. NF-jB p65 levels in the (a) cytoplasm and (b) nucleus were analysed by Western blotting. Total protein levels of (c) phosphorylated IjB and (d) NF-jB p65 were analysed by Western blotting. b-actin or lamin B was used as a loading control. The data shown are representative of four independent experiments. Data are expressed as mean 6 standard deviation (s.d.); *P < 0Á05; **P < 0Á01; ***P < 0Á001.
PD-L1 and spleen lymphocyte activation that PD-L1 alone induces the differentiation of naive CD4
1 T cells into FoxP3 1 -induced regulatory T (iT reg ) cells, which play a pivotal role in suppressing effector T cells and maintaining peripheral tolerance. Wang et al. [28] have also shown that PD-L1 promotes T cell activation through receptors that remain unidentified. In addition, PD-L1 binds PD-1 and mediates an inhibitory signal. Our results reveal that sepsis-associated suppression of IFN-g and IL-2 secretion and the proliferative response of splenic lymphocytes is ameliorated by FTI-277. Furthermore, we showed that the sepsis-induced apoptosis of lymphocytes is alleviated following treatment with FTI-277. These results also support an overall negative regulatory function of PD-L1. Sepsis-associated expression of PD-L1 has been identified as a strong inhibitor of the immune response in spleen lymphocytes. The production of IFN-g and IL-2 by spleen T cells was up-regulated significantly as a result of the FTI-277-mediated damping of the PD-L1 signal in the lymphocytes of septic mice. Moreover, FTI-277 was found to promote spleen lymphocyte activation by attenuating apoptosis and ameliorating the proliferative response of splenic lymphocytes. The present study indicates additionally that IFN-g and IL-2 production is promoted in sepsisassociated lymphocytes following treatment with PD-L1 blocking mAbs (MIH1).
Numerous studies of the expression of PD-1 and PD-L1 in septic mice relative to sham-treated animals, in terms of levels of mRNA transcription and immunohistochemistry, have been reported [7, 14, 29] . Our previous study revealed that FTI-277 down-regulates PD-1 and PD-L1 expression on splenic CD4 T cells and macrophages relative to levels with vehicle alone. However, the potential function of this phenomenon has still not been described [13] . The present study shows that mRNA transcription and protein expression of PD-L1 is upregulated in septic mice. We showed additionally that FTI-277 effectively inhibits the sepsis-induced up-regulation of PD-L1 mRNA and protein expression. Furthermore, we demonstrated that FTI-277 induces down-regulation of PD-L1 in septic spleen lymphocytes in a dose-dependent manner. These results suggest that PD-L1 plays a role in the development of sepsis and that FTI-277 represents a potential therapeutic agent for the treatment of this condition.
The rapid activation of the NF-jB pathway in sepsis has been reported widely [30, 31] ; upon activation, NF-jB in turn activates rapidly the expression of a large number of genes, including PD-L1 [17] . Also, Takada et al. [32] showed that FTI-277 suppresses the activation of IjBa kinase (IKK), thus abrogating the phosphorylation and degradation of IjBa. In addition, FTI-277 down-regulates the expression of certain genes that are regulated by NF-jB; this may be attributable to the inhibition of NF-jB activation. Further studies are needed in order to elucidate the precise interactions between FTI-277, PD-L1 and NF-jB.
We studied the FTI-277-mediated down-regulation of PD-L1 expression in septic mouse lymphocytes and found that the experimental septic group exhibited a significant promotion of NF-jB translocation relative to that in the control group. However, FTI-277 treatment attenuated NFjB translocation and PD-L1 expression significantly in mouse lymphocytes. In addition, we established that the effects of FTI-277 in mice with sepsis are similar to those of PDTC, an NF-jB inhibitor. Our data suggest that the FTI-277-mediated inhibition of NF-jB activation contributes to the prevention of increased PD-L1 expression in septic mice, but the data do not exclude the possibility that the inhibition of NF-jB could be a consequence rather than a mechanism of decreased apoptosis of immune cells and subsequent reduced bacterial burden. Therefore, the precise mechanisms by which FTI-277 inhibits NF-jB activation and induction of PD-L1 expression remain to be clarified.
The farnesyltransferase inhibitor FTI-277, which was developed initially as an anti-cancer drug, has been tested extensively in clinical trials [33] . These results indicate that FTI-277 exhibits anti-inflammatory, anti-cancer and anti-malarial activity. However, the precise mechanisms underlying these effects are not known. FTI-277 has also emerged as a potent target for the treatment of malaria [34] . Our previous data have shown that FTI-277 reduces mortality in mice with sepsis, along with improved bacterial clearance.
Multiple studies have revealed that PD-L1 is upregulated significantly in various kinds of tumour tissues or tumour cell lines stimulated with TNF-g or IFN-g and that blockade of PD-L1 elicits therapeutic immunity in cancer [3, 35, 36] . Our study has identified for the first time that FTI-277 could regulate the expression of PD-L1 in protein and DNA molecular levels and induced downregulation of PD-L1 in septic spleen lymphocytes in a dose-dependent manner. Our study of CD4 1 T cells also testified that FTI-277 promotes spleen lymphocyte activation. Conversely, we made a preliminary exploration of the relationship of FTI-227, NF-jB and PD-L1, and reached an initial conclusion. In future studies, we aim to examine the detailed mechanism by which FTI-277 inhibits farnesyltransferase to improve survival rates in mice with sepsis in order to elucidate further the role of the immune response in the development of sepsis. Additional studies are necessary to determine whether FTI-277 represents a therapeutic agent with potential clinical utility. In summary, this study provides preliminary data describing the molecular mechanism by which FTI-277 down-regulates PD-L1 expression and shows that this effect is largely dependent upon the suppression of the NF-jB signalling pathway. FTI-277 represents a potential immunotherapeutic agent for the treatment of sepsis.
